

Review Article

Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis

Agata N. Burska,¹ Laura Hunt,¹ Marjorie Boissinot,² Rocky Strollo,³ Brent J. Ryan,⁴ Ed Vital,¹ Ahuva Nissim,³ Paul G. Winyard,⁵ Paul Emery,¹ and Frederique Ponchel¹

¹ Leeds Institute of Rheumatic and Musculoskeletal Disease, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Trust Teaching Hospital, Leeds LS9 7TF, UK

² Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK

³ Centre for Biochemical Pharmacology Research Unit, William Harvey Research Institute, Barts and London, Queen Mary's School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1M 6BQ, UK

⁴ Department of Physiology, Anatomy and Genetics, University of Oxford, Le Gros Clark Building, Oxford OX1 3QX, UK

⁵ University of Exeter Medical School, St. Luke's Campus, Exeter, Devon EX1 2LU, UK

Correspondence should be addressed to Frederique Ponchel; mmefp@leeds.ac.uk

Received 8 October 2013; Accepted 10 February 2014; Published 23 March 2014

Academic Editor: Jean Sibilia

Copyright © 2014 Agata N. Burska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Autoantibodies have been associated with human pathologies for a long time, particularly with autoimmune diseases (AIDs). Rheumatoid factor (RF) is known since the late 1930s to be associated with rheumatoid arthritis (RA). The discovery of anticitrullinated protein antibodies in the last century has changed this and other posttranslational modifications (PTM) relevant to RA have since been described. Such PTM introduce neoepitopes in proteins that can generate novel autoantibody specificities. The recent recognition of these novel specificities in RA provides a unique opportunity to understand human B-cell development *in vivo*. In this paper, we will review the three of the main classes of PTMs already associated with RA: citrullination, carbamylation, and oxidation. With the advancement of research methodologies it should be expected that other autoantibodies against PTM proteins could be discovered in patients with autoimmune diseases. Many of such autoantibodies may provide significant biomarker potential.

1. Introduction

Specificity and memory are the hallmarks of the adaptive immune system. Immunological memory is well recognised but still not fully understood. It was first observed in antiquity, during the plague infection in Athens. It is also the basis of vaccination, which was first attempted in India over a thousand years ago when smallpox inoculation to healthy people resulted in a milder epidemic, while protection lasted many years, particularly in the absence of reexposure to the antigen. Molecular immunology has now unravelled the early steps towards the establishment of immunological memory; however, several areas remain unexplained particularly the mechanism of plasma cell development and maintenance. The recent recognition of the specificity of novel autoantibodies in rheumatoid arthritis (RA) provides a unique

opportunity to understand human IgG and B-cell memory development *in vivo*.

The early phases of B-cell development are well established. Initially, naive B-cells are released in the circulation, where they meet with their antigens, becoming activated B-cells. At this stage several models have been proposed and IgG can develop through different routes, in a T-cell dependent or independent manner. In a (classic) linear model [1], maturation occurs in the presence of T-cells in a germinal centre-like reaction (GCR); B-cells switch from secreting IgM to secreting IgG and undergo affinity maturation. Some of these B-cells then develop into memory B-cells and others into long-lived plasma cells (LL-PC). These LL-PC then move to a bone marrow niche where they can survive for years. They are dependent on CXCL12 expression. In a variation of this model, activated B-cells go through a short-live plasma

cell (SL-PC) stage before fully maturing into LL-PC [2]. In a third model both LL-PC and SL-PC secreting IgM and IgG were shown to develop directly from activated B-cells, independently of T-cell help. However this only occurs in the presence of antigen and alternative signals provided by innate immunity mechanisms such as direct TLR activation of B-cells [3]. It appears that these three models may actually coexist providing a first line of defense with rapid secretion of antibodies. However, further T-cell mediated maturation is necessary for a second line of defense involving long-term memory and LL-PC [4]. An inflamed environment such as the synovial membrane in RA (where CXCL12 is highly expressed in active disease [5]) is believed to provide an alternative niche for the survival of LL-PC.

Autoantibodies have been associated with human pathologies for a long time, particularly with autoimmune diseases (AIDs). Organ specific AIDs involve single or multiple autoantigens. In RA, autoantibodies have long been associated with the disease. Rheumatoid factor (RF), an autoantibody reacting against the Fc portion of IgG antibodies, was identified in the late 1930s. It was the most significant biomarker associated with RA until the discovery of anticitrullinated protein antibodies (ACPA). More recently, other posttranslational modifications (PTM) have been associated with the generation of specific autoantibodies that can be used as biomarkers [6–10]. While proteins are encoded by different sequences of amino acids, there are many ways to modify amino acids once introduced in protein sequences. Glycosylation, citrullination, methylation, acetylation, and ubiquitination are all types of physiological modifications. Other modifications can occur due to interaction with foreign substances (i.e., infections), environmental damage (such as UV exposure or chemical pollutants) leading to the formation of chemical adducts on the protein. Modifications including carbamylation, acetylation, ethylation, or methylation were sufficiently immunogenic to produce specific antibodies to these modified sequences of amino acids [11]. The analysis of autoantigen specific B-cell differentiation and maintenance, at the different stages of RA progression, provides a unique opportunity to understand disease and study immunological B-cell memory *in vivo* [12, 13].

Many AIDs are characterized by chronic inflammation, which may play a major role when inflammation-associated events such as chemical or enzyme-mediated modification of protein provide a source of neoepitopes that can be recognised by antibodies as non-self. In situations of stress such as inflammation, all types of physiological responses can be used in an abnormal manner. Citrullination is an enzymatic PTM which has an important role in the normal function of the immune system, epidermis differentiation insulation of neurons and the plasticity of the central nervous system [14]. Chlorination of protein occurs via the conversion of hydrogen peroxide to reactive chlorine species, such as HOCl, by granulocytes notably during inflammation. Other forms of oxidation result from the formation of reactive species of oxygen, nitrogen, and sulphur as a cellular response to various stimulations by growth factors or cytokines [15]. Oxidation products of sugars and unsaturated lipids can also

react with proteins to cause chemical modifications. Nonenzymatic glycation is a naturally occurring phenomenon leading to development of PTM of proteins, nucleic acid, or lipids; it occurs in presence of high blood glucose but is also associated with aging and other inflammatory or degenerative diseases [16] such as RA [17], osteoarthritis [18], and Alzheimer's disease [19–21]. Carbamylation is a nonenzymatic, irreversible PTM. Carbamylation of proteins, lipids, peptides, and amino acids is widespread in health in mammals and is a natural physiological phenomenon. However excessive carbamylation will appear once proteins are exposed to high concentrations of isocyanate derived from the increased dissociation of urea and this alters the function of proteins [22].

Important evidence that perturbations in protein structures introduced by PTM are important in RA was brought by studies of collagen II (CII) for which PTM were shown to dramatically alter immunogenicity [6, 23–25] rendering some of them arthritogenic [26–30]. CII is the predominant cartilage collagen and a known autoantigen [23, 31, 32]. The human joint contains abundant CII and collagen-induced arthritis is the common experimental animal model of RA [33, 34]. Thus, antibodies to CII should be of highest relevance in RA [32]. Nevertheless, antinative CII antibodies occur only in 3–27% of patients with RA [29, 35–37] and, as such, it has been difficult to substantiate the role of autoimmunity to CII in the pathogenesis of RA. However today autoimmunity to PTM CII has been clearly demonstrated (cit-CII [24], ROS-CII [6, 7, 10, 38], although specific anticarbamylated CII remains to be demonstrated in human sera). These findings support the possibility that chemical modification of self-antigens, in RA in particular and in inflammation in general, may be the cause of formation of neoepitopes leading to autoimmunity [16, 39].

2. Anticitrullinated Protein Antibodies (ACPA) in RA

ACPA were originally described using different names such as anti-keratin (AKA), antiperinuclear factor (APF) antibodies, antiflaggrin antibodies (AFA), or anti-Sa [40]. ACPA have been associated with human pathology [41] as well as pre-clinical disease since the early 90s [42] later confirmed [43, 44]. The importance of these antibodies was then recognised several years later when their presence was identified as a specific event associated with RA [45–50]. Many reports were published; however, their relevance was reduced to a few publications where appropriate controls and procedures had been followed, particularly with respect to the ELISA assays used to detect ACPA [51, 52]. In the early years, the use of ELISA for individual reactivities (citrullinated filagrin or keratin) or “first generation” commercially available ELISA kits (CCPI, Immunoscan RA, Euro-diagnostica [53]) showed equal reactivity between RA (22%), healthy control sera (27%), and all kinds of arthritis and inflammatory diseases [49] although clear differences in titres were observed (sensitivities 45–64% but specificity over 90%). Later, “second-generation” ELISAs, showed higher specificity (~98%) and sensitivity

(40–76% depending on disease stage) [54]; however, more recent work also showed potential association of ACPA with psoriatic arthritis [55], periodontitis [56], and osteoarthritis [38]. The main difference between these tests resided in the antigens used to detect ACPA. The diagnostic value of ACPA were therefore established by demonstrating the importance of using appropriate citrullinated peptide [40, 51, 57]. The development of a highly sensitive noncommercial ELISA, based on protein targets identified as reactive with ACPA in synovial tissue (i.e., alpha and beta fibrinogen) was therefore explored [58]. Importantly, positivity of ACPA for one or both to these two citrullinated peptides covered all reactivity in RA sera [59].

2.1. Citrullination. ACPA represent a family of autoantibodies. However, only IgG-isotype of ACPA is specifically associated with RA. The antigen which triggers the immune reaction recognized by ACPA lies in the modification of protein (i.e., citrullination). In summary, after years of research, it was shown that this modification converts an arginine into a citrulline amino acid residue (citrullination) and is performed by an enzyme, peptidylarginine deiminase (PAD), thereby producing the immunogenic epitopes (Figure 1(a)) [60]. A consensus sequence, present in a wide range of proteins, is required for the modification of the arginine residue by the PAD. Metabolic stress related citrullination has also been proposed to play a role in multiple sclerosis [61, 62], Alzheimer's disease [20, 21], and cancer [63, 64]. The modifications introduced by PAD enzymes have important physiological roles, especially during differentiation, development, and apoptosis. PAD enzymes are expressed in a wide range of tissues (epidermis, sweat glands, hair follicles, ovary, and testis). In the synovium, only the enzymes PAD 2 and 4 are expressed; however, their expression is not specific for RA as they are also found in other forms of inflammatory and noninflammatory arthritis [65]. How both intracellular and extracellular proteins are citrullinated remains at the centre of many debates. PAD enzymes are necessary to catalyse protein deimination. PADs are not actively secreted in the intercellular space, although quite a few of their targets are extracellular proteins. Two immune-mediated membranolytic pathways (mediated by perforin and the membrane attack complex MAC), which are active in the RA joint and of importance in RA pathogenesis, have been proposed as possible ways by which PADs may be released in the joint microenvironment [66]. Several human citrullinated proteins have now been identified as target antigens of ACPA in RA (collagen, fibrinogen, vimentin, enolase, etc.) [40, 58, 59, 67, 68]. ACPA recognise citrullinated cross-reactive proteins but it is the presence of ACPA that is specific for RA rather than their protein antigens. The local context in which the proteins targeted for citrullination are expressed does not seem to have much importance; for example, filaggrin, which is an epithelial target of ACPA in RA, is not expressed in synovial tissue [58].

2.2. Clinical Relevance of ACPA. In RA patients, the presence of ACPA was associated with progressive and destructive

disease outcomes [69–71], X-rays demonstrating the presence of erosions earlier and at a greater frequency in ACPA+ patients [72]. ACPA positivity was also associated with the presence of RF and shared epitope (SE) [50]. Combination analysis showed independent additive effects of these three factors for high radiological risk [35, 50, 69, 73]. Furthermore, the extraarticular manifestations that often determine the severity and comorbidity of RA were also closely associated with ACPA positivity [74]. Therefore, although disease onset can follow a similar course, the erosive and destructive nature of ACPA+ RA has resulted in clinicians and scientists considering the diseases as two distinct entities [75]. The main clinical use of these antibodies is however their diagnostic value, now recognised for over 25 years [45–50, 76] but only more recently used as a diagnostic biomarker. Sensitivity (~40%) and specificity (over 95%) of ACPA as diagnostic biomarker are now recognised in early inflammatory arthritis patients with a suspicion of RA [54].

A study using matched serial serum samples (blood donations) from early RA patients with short disease duration highlighted the importance of ACPA in predicting disease severity [50, 77]. The results also showed that radiological damage was more apparent in the groups which had been ACPA+ even before diagnosis was achieved. Radiological progression was also more substantial in this group after 2 years of follow-up. Importantly, these associations were not observed with RF. In contrast, ACPA titres were reduced over the course of disease when patients had a good response to therapy and titres of ACPA at baseline were higher in patients with poorer response. Taking this a step further, van Gaalen and colleagues prospectively studied a cohort of patients at an earlier stage of the disease in order to determine which markers may predict disease progression and persistence [78]. Individuals with an inflammatory arthritis but who did not fulfill the American College of Rheumatology (ACR) classification criteria were recruited. Multivariate analysis confirmed ACPA as an important independent predictor of RA with 93% developing RA within 3 years if ACPA+ at baseline. Given the clinical relevance of ACPA, it is not surprising that the new ACR/European League Against Rheumatism (EULAR) 2010 RA classification criteria have included ACPA titre in order to improve the diagnosis of early RA [79].

Studies which have evaluated ACPA titres while treating RA are emerging with variable observations (recently reviewed in [80]). Conventional antirheumatic drugs (DMARDs, including methotrexate, hydroxychloroquine, minocycline, or sulfasalazine) induce a marginal reduction in ACPA titres (>25%) over the course of treatment in about 50% of patients and a more pronounced decrease (>50%) in less than 30% of patients [81]. Response to TNF blockade was associated with lower baseline titres for ACPA, other clinical parameters being similar [82]. Response was also associated with a sustained reduction in ACPA titres, other studies showing similar ~30% reduction of serum ACPA titres after anti-TNF treatment [81–92]. However, several other reports showed little or no effect on ACPA titre [93–97]. Therapeutic B-cell depletion (using Rituximab an anti CD20 antibody depleting naive, memory, and preplasma cells but not plasma




FIGURE 1: (a) Enzymatic generation of citrulline from arginine catalyzed by peptidylarginine deiminase (PAD); (b) non-enzymatic formation of homocitrulline by carbamylation of lysine by cyanate; (c) products of reactions between tyrosine with reactive oxygen species (forming dityrosine), reactive nitrogen species (forming 3-nitrotyrosine) and reactive chlorine species forming 3-chlorotyrosine; (d) examples of AGEs formed including carboxymethyl arginine and pentosidine (formed between an arginine and lysine residue).

cells) has marginal effect on ACPA titres [98–101] or not at all [102]. Significant reductions of ACPA titres were only observed in patients who responded to chemotherapy and higher titers of ACPA were associated with lack of clinical improvement [103].

3. Anticarbamylated Protein Antibodies (Anti-CarPA) in RA

The first demonstration of the deleterious effects of protein carbamylation in humans was made in the 1970s [104]. The quantification of carbamylation-derived products (CDPs) remains rarely used in clinical practice [105] and evaluation of antibodies against carbamylated proteins is just emerging.

PTM through carbamylation has been implicated in vascular dysfunction in renal disease, atherosclerotic plaque formation [106], and antibiotic resistance [107].

3.1. Chemical Reaction. Unlike citrullination which is catalyzed enzymatically, carbamylation (often referred to as homocitrullination) is a chemical modification. It can occur ubiquitously in the presence of the reactive metabolite, cyanate. One of the cyanate sources is the spontaneous degradation of urea, which is constantly and ubiquitously generated in the body and always in equilibrium with cyanate. Therefore, wherever there is urea, there is cyanate and the potential for homocitrullination. However, under normal physiological conditions, concentrations of both are too low for any significant proteins modification.

Theoretically, any protein can be carbamylated *in vivo*. However, the susceptibility of each protein to such modification depends on various parameters, such as the number and accessibility of lysine and arginine amino groups, and the protein lifespan. As carbamylation is nearly irreversible, it is more likely to affect long-lived proteins as they may acquire homocitrulline residues over time [9]. Various CDPs can be formed, among them α -carbamyl-amino acids (or α -carbamyl-proteins) when α -amino groups are involved, and ϵ -carbamyl-lysine, also called homocitrulline, when ϵ -amino groups are involved (Figure 1(b)) [104]. The carbamylation of amine groups leads to a change in the charge of the molecule. Carbamylated derivatives may therefore acquire biological and antigenic properties that are different from those of the noncarbamylated molecules. On the other hand, carbamylation-induced conformational changes in proteins are also associated with partial or complete loss of protein functions [26], inhibition of enzymatic activities particularly relevant in RA such as matrix metalloproteinase-2 [108] or tissue inhibitor of metalloproteinase-2 [109], modification of hormonal activities (i.e., insulin [110], glucagon [111], adrenocorticotrophic hormone [112], and erythropoietin [113]), and by affecting proteins such as haemoglobin [114], albumin [115], and collagen [116, 117].

3.2. Clinical Relevance. Carbamylated proteins may have a role in inflammation and as such in RA. They can modulate the functions of inflammatory cells, as evidenced by the inhibitory effect of carbamylated-albumin on the polymorphonuclear leukocyte respiratory burst [115, 118]. Carbamylation of low density lipoproteins (LDLs) by myeloperoxidase (MPO) seems to play a pivotal role in atherosclerosis [119–122] as well as in inflammation [106, 122–124]. Carbamylated collagen stimulates the production of active matrix metalloproteinase-9 (MMP-9) by monocytes, thus potentially enhancing extracellular matrix turnover [104, 125]. Therefore it is intriguing that homocitrulline also represents an immune target in RA.

In 2010, the presence of anti-CarPA (also called anti-homocitrullinated protein/peptide antibodies; AHPA) was demonstrated [26] in human sera and in an animal model of autoimmune arthritis expanding the set of known autoantibodies related to RA. Reactivity to carbamylated animal protein has been reported but the exact nature of the autoantigens recognised by anti-CarPA remains elusive. Fibrinogen is extensively accessible to homocitrullination and there are substantially more potential amino acid residues available for this type of modification in this molecule compared to citrullination [118]. The generation of antibodies to carbamylated regions of fibrinogen in RA patients was confirmed [118]. The RA specificity of anti-CarPA was suggested ($n = 84$) as these antibodies were not found in patients with other inflammatory rheumatic conditions SLE ($n = 37$, 5% weakly positive results) and psoriatic arthritis ($n = 37$, 3% weak reactivity) or normal healthy individuals ($n = 27$). The fact that some RA patients have reactivity to carbamylated but not citrullinated fibrinogen supports the concept that homocitrullination can generate unique structural antigens on proteins, that is, although cross-reactivity between ACPA

and anti-CarPA was recently reported [118]. In another study carbamylated vimentin was used to detect anti-CarPA in RA patients [126]. Carbamylated vimentin was significantly more reactive than carbamylated enolase which suggests that the amino acids surrounding the modification (or even the whole molecule) are contributing to its immunogenicity [126]. The known association between ACPA and MHC class II SE expression [127, 128] was very recently supported for anti-CarPA with data showing that homocitrulline and homocitrullinated peptide could potentially bind to the SE [118].

Anti-CarPA IgG were found in the serum of 45% of RA patients and IgA anti-CarPA in 43% [9]. The presence of anti-CarPA partially overlapped with the presence of ACPA, but most interestingly was also found in 16% of RA ACPA– patients (30% were positive for anti-CarP IgA) [9]. The presence of anti-CarPA was detected in over 30% of such patients when ACPA– therefore offering an alternative biomarker to help the diagnostic of RA [9]. Furthermore, anti-CarPA positivity was related to clinical outcome [9]. Detection of anti-CarPA at disease presentation was predictive of a more destructive disease course (evaluated using Sharp-van der Heijde scores). Importantly, this was verified in both ACPA+ and ACPA– RA, notably offering a novel biomarker for the diagnostic of RA and, furthermore, a clinically useful prognostic biomarker for ACPA– disease.

In individuals with seropositive arthralgia (340 patients positive for rheumatoid factor (IgM-RF) and/or ACPA+), the prevalence of Anti-CarPA was 39% [129]. The presence of anti-CarPA did not correlate with RF. Anti-CarPA were associated with progression towards RA. Furthermore, established association indicated that anti-CarPA positive arthralgia patients were more likely to develop RA and notably within a shorter time frame compared to individual with only RF and/or ACPA positivity. Such increased risk of developing RA was maintained in double positive ACPA/anti-CarPA arthralgia patients even after correction for ACPA. Higher anti-CCP antibody levels were also observed in anti-CarPA positive patients. These observations suggest that alternative seropositivity in RA patients may each represent a different disease entity with its own genetic/environmental contributions [129, 130].

Despite these promising initial findings, further research is needed to clarify anti-CarPA responses and how they could contribute to the clinical management of RA. Additional studies using patients with a suspicion of RA as controls are needed to determine the specificity of anti-CarPA for RA diagnostics. Whether their presence predicts the development of (ACPA–) RA in patients suffering from unclassified joint complaints such as arthralgia or early signs of inflammatory arthritis remains to be established [9, 130]. Links with environmental factors (smoking, alcohol intake, body mass, hormonal status, periodontal disease, etc.) remains to be elucidated. Despite the association with SE, other genetic factors may be relevant. Early aggressive treatment in RA has been shown to prevent future damage [131, 132]. The clinical utility of a prognostic biomarker such as anti-CarPA in the management of ACPA– patients with respect to their risk of developing a more severe disease remains of great interest [9].

4. Antioxidized Protein Antibodies in RA

Oxidative stress is a term that is used to describe situations in which an organism's production of oxidants exceeds the capacity to neutralize them. The consequences are damages to cell membranes, lipids, nucleic acids, proteins, and constituents of the extracellular matrix such as proteoglycans and collagens. Several lines of evidence suggest a role for oxidative stress in the pathogenesis of RA [133–139]. Epidemiologic studies have shown an inverse association between dietary intake of antioxidants and RA incidence [140–143], and, reciprocally, an inverse association between antioxidant levels and inflammation [39, 144, 145]. Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen (such as superoxide and peroxides), and a natural byproduct of the normal metabolism of oxygen. ROS are able to oxidize various amino acids, according to their oxidation potential. They have important physiological roles in cell signaling, apoptosis, ion transport systems, wound healing and blood homeostasis, and also the induction of host defense (respiratory burst), genes, and inflammatory responses. They can also be detrimental in situations of stress when their levels dramatically increase to the point of harming cells. This notably occurs when antioxidants normally protecting cells (superoxide dismutases, catalases, peroxidases, peroxiredoxins, and others) are unable to manage the amount of ROS produced [146].

Oxidative modifications by ROS are attractive candidates as instigators of autoimmunity and this might involve a process of “oxidative PTM intolerance” [10], resulting in a primary B-cell response against the posttranslationally modified self-antigen [10]. Oxidative stress-induced antibodies to carbonyl-modified protein have also been found to correlate with severity of chronic obstructive pulmonary disease [147] and SLE [148].

4.1. Chemical Reaction. Oxidative stress occurs during inflammation and causes proteins to become damaged by reactive species such as reactive oxygen, nitrogen, and chlorine species. NADPH oxidase is a major source of ROS in arthritic joints. This enzyme reduces O_2 generating large amounts of superoxide radical anion $O_2^{\bullet-}$, which is considered the primary ROS and may be further reduced to H_2O_2 , which in turn can be converted into highly reactive $^{\bullet}OH$ or react with Cl^- to generate HOCl (in a reaction catalyzed by the enzyme myeloperoxidase). iNOS also generates $^{\bullet}NO$ which is converted to ONOO $^-$ by reacting with $O_2^{\bullet-}$ [149, 150]. In addition, under conditions of oxidative stress, species such as peroxynitrite (ONOO $^-$) may be generated resulting in nitration of tyrosine residues to form 3-nitrotyrosine (3-NT) (Figure 1(c)) [138, 151, 152]. Indeed, antibodies recognizing 3-NT have been identified in the synovium of RA patients and correlate with disease activity [152].

In addition, these reactive species generate “secondary” reactive species such as lipid peroxidation products. Nonenzymatic oxidation by sugars can react directly or generate reactive products such as glyoxal and methylglyoxal; these reactive carbonyls are capable of undergoing Maillard reactions, first forming a Schiff base with the amine group

of amino acids, such as lysine or arginine. This intermediate can then undergo an Amadori rearrangement to form stable advanced glycation end product (AGE) such as carboxymethyl arginine or initiate peptide cross-linking to form pentosidine (Figure 1(d)) [153]. The presence of these PTM on protein increases as well as modifies their natural antigenicity and antibodies against the native and modified forms of these proteins are usually noncross-reacting and were detected in RA despite the absence of hyperglycemia [17, 154]. AGEs can have damaging effects on collagens by forming irreversible cross-links between the fibers in the triple helix [155–158].

Another potential reaction is chlorination of aromatic amino acids, in particular tyrosine residues, including 3-chlorotyrosine, within the polypeptide backbone (Figure 1(c)) [159]. Under conditions of oxidative stress, species such as peroxynitrite (ONOO $^-$) may be generated resulting in nitration of tyrosine residues to form 3-nitrotyrosine (3-NT) (Figure 1(c)) [138, 151, 152]. Indeed, antibodies recognizing 3-NT have been identified in the synovium of RA patients and correlate with disease activity [152]. Exposure of collagens to peroxynitrite results in nitration of tyrosine residues and formation of posttranslationally modified nitrotyrosine. These compounds are negatively charged and further disrupt the collagen structure. ROS levels are increased in autoimmune diseases such as RA and SLE. The overproduction of ROS may exceed the capacity for radical scavenging by antioxidant enzymes or small inhibitors. Exposure of proteins, nucleic acids, or cell membrane and free lipids to ROS modifies amino acids creating PTM proteins and lipids by initiation of peroxidation. There is no recognized specificity to the protein that can be modified and oxidation depends on steric and stochastic factors; however, enrichment for amino acid motif YXXK in the vicinity of chlorination has been observed [160]. Oxidized proteins identified in RA include collagens I, II, IX, and XI, proteoglycans, and hyaluronan. Increased oxidation of lipids is also a known feature of RA, with the appearance of foam cell-like structures within the rheumatoid synovium [39, 136, 161].

In the context of RA, immunoglobulins themselves can undergo glycation to generate AGE-IgG. Autoantibodies to such modified-IgG were also shown to be specifically associated with RA, whereas the actual formation of AGE-IgG was directly related to the intensity of the inflammatory response but was not specific to RA [162–164]. Similarly, modification of IgG by HOCl or peroxynitrite can induce a T-cell response against IgG HOCl and peroxynitrite in RA [165].

4.2. Clinical Relevance. The key ROS present in inflamed joints are superoxide radical ($O_2^{\bullet-}$), hydrogen peroxide (H_2O_2), hydroxyl radical ($^{\bullet}OH$), hypochlorous acid (HOCl), nitric oxide ($^{\bullet}NO$), and peroxynitrite (ONOO $^-$), which are involved in acute and chronic inflammation [6, 15]. Such ROS have been identified in synovial fluid of 90% of patients with RA, with a shift in the oxidant/antioxidant balance in favour of lipid peroxidation, which lead to the tissue damage observed in joints [166, 167].

Exposing CII to conditions which simulated those found in an inflamed joint, resulted in chemical modifications of native CII [6]. CII treated with hydroxyl radical ($^{\bullet}\text{OH}$ -CII), hypochlorous acid (HOCl -CII), and peroxynitrite (ONOO^- -CII) demonstrated positivity for binding to autoantibody specifically recognizing these various CII-modified forms in sera from 93 of early RA patients in addition to glycation of CII (Gly-CII) carried out with ribose. No cross-reactivity with native CII was observed but reactivity to native CII was seen in <20% of sera [6]. Moreover, no anti-ROS-CII reactivity was detected in other inflammatory arthritis conditions (including psoriatic arthritis, SLE, ankylosing spondylitis, palindromic arthritis, scleroderma, Behçet's disease, primary Sjögren's syndrome, fibromyalgia, tendonitis and reactive arthritis [6]).

In 2005 we showed that CII post-translationally modified by ROS (ROS-CII), present in the inflamed joints, is an autoantigen in RA [6]. In addition, cartilage damage as a result of collagen oxidation by glycation and formation of AGE-CII are evident despite the absence of hyperglycemia [168].

We have recently measured auto-reactivity to ROS-CII in synovial fluid (SF) and serum samples taken from various phases of RA [38] and demonstrated that anti ROS-CII reactivity is not related to markers of inflammation such as CRP and ACPA and has potential to serve as biomarker for several purposes. We observed high anti-ROS-CII reactivity in DMARD naïve early RA regardless of whether patients were ACPA+ or ACPA- and with no correlation with DAS28. The sensitivity and specificity of the binding of autoantibodies to ROS-CII in early RA compared with healthy controls (HC) was 92% and 98%, respectively. ROS-CII reactivity was lower in RA patients having received their first DMARDs treatment and achieving a good response. We also showed that anti-ROS-CII reactivity considerably vary over time in a mixed cohort of RA patients with established disease on several type of treatment [38]. This was in contrast to levels of ACPA which did not. We could not directly associate these changes with DAS28, however, patients in this cohort all had (very) active disease and it was impossible to fully ascertain longitudinal variation between active/remitting diseases.

Further pilot data showed that in a small cohort of ACPA+ arthralgia patients with no synovitis, only those within a few weeks (~12) of developing clinical evidence of synovitis were positive for anti-ROS-CII reactivity while those who developed symptoms after a much longer delay were negative. Interestingly, in a study conducted in type 1 diabetes, a condition associated with RA [169], anti-ROS-CII reactivity was restricted to SE-containing DRB1*04 alleles (OR 3.62; 95% CI 1.12–11.74), known to confer the greatest risk for developing RA. Further work needs to establish whether patients with inflammatory synovitis but not yet RA (i.e., undifferentiated arthritis) would be positive however, 93% of early RA were, which altogether, strongly suggest a direct association with the development of synovitis, hence offer a measurable biomarker of disease development alongside the RA continuum [38].

Anti-TNF treatment showed reduction in oxidative stress, and these correlated with an improvement in disease activity [170–173]. However studies evaluating changes in anti-ROS

autoantibody levels after RA anti-TNF treatment are still missing. Our own data however suggest variation [38] which will need to be confirmed before any biomarker value can be confirmed.

In addition to CII, studies of RA synovial fluid and tissue have demonstrated oxidative damage to hyaluronic acid [174], lipid peroxidation products [175, 176], oxidized low-density lipoproteins (ox-LDL) [136], and increased carbonyl groups reflective of oxidation of other proteins [136, 162, 177–179]. Evidence of oxidative damage to cartilage, extracellular collagen, and intracellular DNA has also been demonstrated. Protein chlorination occurs in RA at the disease site (i.e., synovial fluid and tissue) [159, 180] and it was proposed that this could be the link between arthritic inflammatory reactions and the initiation of autoimmune antibody responses. The risk associated with ox-LDL in RA is mostly related to cardiovascular risk hence not specific to RA. Ox-LDL are strong autoantigens, essential to the development and progression of the plaque in atherosclerosis as LDL molecules only become immunogenic due to the oxidative modification during early atherogenesis [181, 182]. Anti-oxLDL antibodies are extensively prevalent in patients with autoimmune diseases, including RA [183], SLE [184, 185], and antiphospholipid syndrome (APS) [186, 187], diabetes mellitus [188, 189], uremia [190]. Anti-ox-LDL antibodies bind ox-LDL and generate immune complexes. Circulating immune complexes are not in themselves harmful. They cause damage only if they are deposited in tissues (notably in the endothelium), resulting in inflammation [191, 192]. T-cells, primarily CD4^+ cells, have been found associated with these immune complex depositions [193–196]. Cardiolipin is also the target of oxidation (ox-CL). Anti-ox-CL antibodies are frequent in APS patients [197, 198] due to formation of neopeptide on cardiolipid, possibly with cross-reactivity with anti-oxLDL antibodies notably in patients with SLE [197, 199, 200].

Finally, autoantibodies targeting AGE-modified IgG are also present in serum of RA patients [154, 201]. Autoantibodies against AGE-IgG might be helpful in monitoring progress in the RA disease continuum and in combination with other clinical features of the RA might be a useful diagnostic tool [201].

5. Animal Model Testing of PTM-Targets and Antibody to PTM-Proteins

An important discovery in the association between anti PTM-protein and RA was the demonstration that these antibodies and their targets are both arthritogenic in animal models. The citrullinated forms of collagen II appeared more arthritogenic in rats than native collagen II [202, 203]. Within the human synovium, the immune reaction between citrullinated fibrin and ACPA results in the activation of effector mechanisms. Immune-complex containing ACPA and CII citrullinated peptide can activate blood macrophages via FcR resulting in the production of TNF-alpha in mice [204, 205]. A similar response by synovial macrophage would promote local inflammation which in turn will favour plasma

extravasation and fibrinogen polymerisation. These deposits then could get citrullinated by locally expressed PAD and therefore become new target for ACPA closing the circle for self-perpetuation. PAD 2 and 4 are expressed in the RA synovium (and in other inflamed tissues) but importantly in correlation with the intensity of inflammation [65]. The arthritogenicity of chlorinated-CII versus native CII (Cl-CII) was also demonstrated in a rat strain [159, 206, 207]. This might be caused by an increased immunogenicity of Cl-CII, resulting in a stronger antibody-inducing capacity. Hydroxyl radical modification of collagen type II (OH-CII) also increases its arthritogenicity and immunogenicity and resulted in an early and more severe arthritis compared to native CII [208].

Anti-CarPA are now extensively studied to clarify whether they are directly involved in the pathogenesis of RA. carLDL induce an IgG response in LDL-R^{-/-} mice and autoantibodies also bind to humans plasma proteins [209]. The immunogenicity and an arthritogenic role of the anti-homocitrulline immune responses were confirmed using animal model of arthritis. Immunization of several mouse lines (NMRI, BALB/c, and C57bl/6) with carbamylated-peptides led to a Tcell dependent activation of B-cell and the production of autoantibody [26]. Direct intra-articular injection of the carbamylated-peptides in these mice induced a severe erosive arthritis [26]. This study was also the first to report the presence of anti-CarPA in RA patients, both in the joints and circulation, and importantly in relation to erosions. Rabbits immunized with carbamylated-proteins resulted in high-affinity antibodies to homocitrulline-containing collagen telopeptides and to less strong anticitrulline-containing telopeptides and mutated citrullinated vimentin [27].

The exact pathogenic potential of anti-CarPA therefore appears to be similar to that of ACPA [210]. The possibility of cross-reactivity between these two antibody types demands further investigation into the identification of true targets in RA. If antibody responses to citrulline and homocitrulline are indeed arthritogenic, important questions remain: which antibodies are pathogenic? Is it the specificity of the target antigen, the quantity, and diversity of the response, and/or merely the binding affinity to available targets in the arthritic joint, which are important in determining arthritogenicity and clinical disease progression [211]?

6. Autoantibodies and B-Cell Development in RA

To date the overall development of the anti-PTM-protein antibody producing B-cell clones remains poorly understood. ACPA of the IgG are the immunoglobulin isotype specifically associated with RA [57]. This suggests that an immune reaction leading to the development of IgG ACPA is taking place at some point before the onset of RA. ACPA of the IgG subclasses 1 to 4, are detected; however a major bias is observed towards an IgG1 (86% alone) and IgG4 but with a very limited involvement of IgG2 and 3 [57]. Such bias correlates closely with an imbalance toward Th1 polarisation which is well described in RA.

The presence of B-cell reactivity to Cl-CII in RA patients was established [6, 38]. Spontaneous production of ACPA could only be obtained from B-cells isolated from the synovial fluid and bone marrow of IgG ACPA+ RA patients. The presence of IgG ACPA up to 15 years before symptoms has also been reported [44, 212]. A cross-sectional study also reported that titres of IgG ACPA appeared higher shortly before the onset of RA suggesting reactivation of the producing B-cells [44]. Finally, the strongest argument in favour of this immune reaction is the T-cell response to citrullinated peptide observed in RA patients but not in healthy controls [213, 214].

The hypothesis that each stage of the disease represents an evolution in ACPA specific B-cell maturation is therefore attractive. At this stage, however, it has not yet been either demonstrated or nullified. ACPA have been shown to be present at detectable levels years before the first manifestation of RA with high risk for these individuals to develop RA within 5 years [22, 124]. In the preclinical phase (ACPA positivity but no disease symptoms), ACPA-IgG circulate (sometimes for many years) suggesting that, at least, isotype-switched ACPA-specific B-cells are present. During this disease initiation phase, cross-sectional analysis also showed that ACPA titres are higher just before onset of symptoms [215–217].

In vivo, differences in ACPA levels [73], fine specificity or epitope spreading [218, 219], avidity [220–222], isotype usage [223], and glycosylation [224] may be associated with differences in the potential to activate effector mechanisms, thereby influencing their biological potency [220]. Epitope spreading is often a hallmark of progressive B-cell responses and was described for ACPA and was associated with an increase and/or shift in antigen recognition during the course of an autoimmune response [218, 225, 226]. Fine mapping analysis of preclinical sera compared to early and established RA showed subtle difference in either the identity or the numbers of epitope detected between the different phases of the disease [43, 215, 216, 227, 228]. Our own unpublished data using the same platform showed a particular epitope detected exclusively in synovial fluid which may represent a unique specificity with local retention of the ACPA (as not detected in sera) suggesting local B-cell reactivity. Despite the association between the presence of anti-CarPA and the broadening of ACPA's fine specificities, anti-CarPA are generated independently of ACPA and, to date, are largely noncross-reactive although the panel of currently available carbamylated antigens remains limited. The effect of anti-CarPA in arthralgia patients is notably independent of the effect of ACPA (after correction) [129]. It will be of great interest to expand the investigation for anti-CarPA and anti-ROS specificities, particularly among ACPA- patients and determine whether these antibodies could have pathological effects in RA patients [229].

A few studies already have shown that circulating ACPA-IgG differ in avidity but still relatively little is known about avidity maturation of ACPA before and during the RA continuum [220]. Lower ACPA avidity was reported in ACPA+ asymptomatic individuals compared to avidity in ACPA+ patients with joint symptoms (arthralgia), which was similar

to avidity observed in established RA patients [221, 222]. Following immunoablative therapy, ACPA-IgG of low avidity developed again which suggested a newly generated autoimmune response [103]. However, the development of high avidity ACPA-IgG remains speculative and their presence may be only characteristic for specific RA patients, refractory, or less responsive to immunosuppressive treatment [103]. As mentioned previously, all immunoglobulin isotypes (IgM, IgA, and IgE ACPA) contribute to overall ACPA activity in RA serum [223, 230, 231]. Although autoantibodies of IgG isotype are generally the most relevant, other studies have shown that IgA were also specific for RA [231, 232]. IgG are associated with radiographic progression in RA [73, 77], but patients positive for IgA-ACPA with recent onset RA were reported to suffer a more severe disease course over the first three years [233] and the higher the number of different isotypes, the greater long-term radiographic joint damage at 5-year follow-up [234]. This data suggests that the development of the anti-CCP isotype repertoire occurs early in the course of arthritis [217, 235].

Glycosylation of the Fc-part of antibodies affects their function with either a pro- or an anti-inflammatory outcome functionality [236]. The glycosylation profile of ACPA in RA is characterised by a low content of galactose (hypoglycosylation) and sialic acid residues [224]. Hypoglycosylation of ACPA was more pronounced than that of total IgG1, resulting in a proinflammatory Fc-glycosylation pattern of ACPA that could be one mechanism driving inflammation in RA [224, 237]. Fc-glycosylation of ACPA showed significant differences between SF and serum and, in contrast to ACPA in serum, ACPA isolated from SF were found to be highly agalactosylated [224]. IgG glycosylation showed association with RA activity [238]; however, this pattern was not useful to predict clinical response to MTX and anti-TNF treatment in RA [239]. Finally, the specific ACPA-Fc hypoglycosylation was detected already 6 months prior to RA onset [237].

TNF- α is an important factor in GCR. If disease initiation was to coincide with a time when B-cells are undergoing early TNF/GCR dependent maturation phases, TNF-blockade in early disease should result in definite ACPA titre reduction. Studies of the effect of TNF blockade in early disease are still lacking and are in progress. In established disease TNF-blockade is clinically efficient but may not be able to interfere with the course of B-cell differentiation anymore; hence studies analysis ACPA titres over the course of anti-TNF therapy in established disease showed variable results. In long lasting RA, B-cell ablation does not result in major ACPA titres reduction in contrast to total IgM titres (but not IgA and IgG) [98–102]. Plasma cells not being directly depleted by the therapy due to the fact that they do not express CD20, suggesting that, in established RA, ACPA-LL-PC are present. The small reduction in ACPA titres reported after B-cell depleting therapy (< than 20–30%) nevertheless suggests that a small pool of ACPA producing cells (memory and SL-PC) are affected by the therapy [240] notably as SL-PC were evidenced in the synovium of RA patients and were shown to secrete autoantibodies including ACPA [241, 242].

The direct analysis of ACPA producing B-cells has proven difficult. The classic molecular tools used to label antigen-specific B-cells have not been very successful to date in isolating ACPA-B-cells (MHC-tetramers, biotinylated-peptide specific for ACPA BCR). ACPA-specific T-cell clones were detected in established disease [213]. However, it remains to be determined whether they play a role in anticitrullination response in RA and most importantly when. The further elucidation of the B-cell maturation path will require serial samples from preclinical stages, then early and fully established disease and the examination of somatic hypermutation and affinity maturation.

Data generated to date therefore establish the presence of an immune reaction resulting in the secretion of ACPA. Yet, the primary stimulus leading to such production remains unknown. An environmental association between the presence of ACPA and smoking has been established [219, 243], and smoking is the most recognised environmental factor reproducibly associated with RA. Recently, silica exposure has also been linked to RA [244–246] and other immunologically mediated diseases [247]. A study looking at the link between genetics and environmental factors has shown that the presence of ACPA was associated with the shared epitope HLA-DRB1 in a dose dependent manner but that smoking was only important in patients positive for ACPA secretion [75, 248, 249]. This observation may suggest that physiological processes associated with smoking have a role in the initial generation of ACPA. A model has been proposed in which smoking (and other agents) triggers the production of IgG ACPA [250]. A second event leads to the citrullination of synovial proteins which would direct ACPA immunity towards the joints [218]. The disease would then be initiated, and, if uncontrolled, become chronic. The role of ACPA in the self-maintenance of RA, once it is established, is a more easily understandable model; however, the exact nature of the citrullinated protein target of ACPA remains elusive.

Therapeutic B-cell depletion results in disease improvement (by 6 to 10 weeks) but not in ACPA serum titres reduction. Synovial depletion of B-cells however is delayed (26 to 30 weeks) probably accounting for the time necessary to eliminate short-live plasma cells from the tissue [98]. Therefore some of the benefit of the therapy must be related directly to the removal of B-cell (not plasma cells) from the tissue. There has been speculation that synovial B-cells in RA may have some unusual lack of responsiveness abolishing their proliferative capability (anergic B-cells) leaving intact their antibody production [251]. Two-way interaction between B-cells and T-cells may be a great relevance here: B-cells provide signals to T-cells through antigen presentation and T-cells provide “help” to B-cells through the delivery of cytokines and cell mediated stimulation, creating a self-sustained feedback loop. Whether B-cells stimulate T-cells to stimulate B-cells, vice versa or, more simply, which cell makes the initial mistake and trigger autoimmunity has been a point of debate for years [252]. In favor of B-cell, an argument has been put forward for CD4⁺ T-cell activation being dependent on B-cells in the synovium, in the context of a GCR and in a HLA-DRB1 restricted manner where the antigen is harbored by the B-cells [253]. Breaking this loop should, in

itself, restore self-tolerance. Therefore, the removal of ACPA secreting B-cell may be more relevant to reestablishing self-tolerance in RA as it may remove ACPA themselves but also the source of activation for the two-way interaction between B- and T-cells.

7. Conclusion

The findings presented in this review support the hypothesis that PTM of self-antigens, in RA and in inflammation in general, are a cause of the formation of neoepitopes giving rise to autoantibodies. Whether the breakdown of tolerance occurs because antibodies against modified self-protein are promiscuous and bind both the modified and unmodified self-antigen or whether they are truly specific for modified proteins is unclear. Nevertheless, these processes contribute to the vicious circle of chronicity by providing novel immune reactivity, resulting in further stimulation of the immune response against self-antigens. With the advancement of research methodology it should be expected that novel specificities of autoantibodies against PTM proteins could be discovered in patients with autoimmune diseases. Many of these autoantibodies could have significant biomarker potential. Clearly, animal models suggested therapeutic advantages in preventing the generation or binding of potentially pathological autoantibodies to the extracellular matrix collagen and collagen-like structures. B-cell responses to native CII have long been known in RA but, as PTM-CII reactivity induces or worsens experimental arthritis, it is possible that blocking PTM could ameliorate arthritis [7, 206]. As such, antioxidants and inhibitors of oxidative enzymes have already been shown to ameliorate arthritis in animal models [254, 255]. The translation of antioxidant therapies to human clinical studies has produced disappointing results, but targeted approaches using novel inhibitors of oxidative enzymes offer new hope for the treatment of RA.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The authors gratefully acknowledge financial support from the IMI-funded project BeTheCure, 115142-2.

References

- [1] G. J. Silverman and S. Weisman, "Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy," *Arthritis & Rheumatism*, vol. 48, no. 6, pp. 1484–1492, 2003.
- [2] S. Crotty and R. Ahmed, "Immunological memory in humans," *Seminars in Immunology*, vol. 16, no. 3, pp. 197–203, 2004.
- [3] T. S. Gourley, E. J. Wherry, D. Masopust, and R. Ahmed, "Generation and maintenance of immunological memory," *Seminars in Immunology*, vol. 16, no. 5, pp. 323–333, 2004.
- [4] A. Radbruch, G. Muehlinghaus, E. O. Luger et al., "Competence and competition: the challenge of becoming a long-lived plasma cell," *Nature Reviews Immunology*, vol. 6, no. 10, pp. 741–750, 2006.
- [5] C. H. Burgoyne, S. L. Field, A. K. Brown et al., "Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse," *Annals of the Rheumatic Diseases*, vol. 67, no. 6, pp. 750–757, 2008.
- [6] A. Nissim, P. G. Winyard, V. Corrigall et al., "Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint," *Arthritis & Rheumatism*, vol. 52, no. 12, pp. 3829–3838, 2005.
- [7] J. Marcinkiewicz, R. Biedron, K. Maresz et al., "Oxidative modification of type II collagen differentially affects its arthritogenic and tolerogenic capacity in experimental arthritis," *Archivum Immunologiae et Therapiae Experimentalis*, vol. 52, no. 4, pp. 284–291, 2004.
- [8] S. M. Anderton, "Post-translational modifications of self antigens: implications for autoimmunity," *Current Opinion in Immunology*, vol. 16, no. 6, pp. 753–758, 2004.
- [9] J. Shi, R. Knevel, P. Suwannalai et al., "Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 42, pp. 17372–17377, 2011.
- [10] P. Eggleton, A. Nissim, B. J. Ryan, M. Whiteman, and P. G. Winyard, "Detection and isolation of human serum autoantibodies that recognize oxidatively modified autoantigens," *Free Radical Biology & Medicine*, vol. 57, pp. 79–91, 2013.
- [11] U. P. Steinbrecher, M. Fisher, J. L. Witztum, and L. K. Curtiss, "Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine," *Journal of Lipid Research*, vol. 25, no. 10, pp. 1109–1116, 1984.
- [12] L. Martinez-Gamboa, H.-P. Brezinschek, G. R. Burmester, and T. Dörner, "Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy," *Autoimmunity Reviews*, vol. 5, no. 7, pp. 437–442, 2006.
- [13] S. Bugatti, V. Codullo, R. Caporali, and C. Montecucco, "B cells in rheumatoid arthritis," *Autoimmunity Reviews*, vol. 7, no. 2, pp. 137–142, 2007.
- [14] Z. Baka, B. György, P. Géher, E. I. Buzás, A. Falus, and G. Nagy, "Citruination under physiological and pathological conditions," *Joint Bone Spine*, vol. 79, no. 5, pp. 431–436, 2012.
- [15] P. G. Winyard, C. J. Moody, and C. Jacob, "Oxidative activation of antioxidant defence," *Trends in Biochemical Sciences*, vol. 30, no. 8, pp. 453–461, 2005.
- [16] M. A. Karsdal, K. Henriksen, D. J. Leeming, T. Woodworth, E. Vassiliadis, and A.-C. Bay-Jensen, "Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease?" *Clinical Biochemistry*, vol. 43, no. 10–11, pp. 793–804, 2010.
- [17] J. Rodríguez-García, J. R. Requena, and S. Rodríguez-Segade, "Increased concentrations of serum pentosidine in rheumatoid arthritis," *Clinical Chemistry*, vol. 44, no. 2, pp. 250–255, 1998.
- [18] P. Richardot, N. Charni-Ben Tabassi, L. Toh et al., "Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis," *Osteoarthritis and Cartilage*, vol. 17, no. 10, pp. 1362–1367, 2009.
- [19] V. P. Reddy, M. E. Obrenovich, C. S. Atwood, G. Perry, and M. A. Smith, "Involvement of Maillard reactions in Alzheimer disease," *Neurotoxicity Research*, vol. 4, no. 3, pp. 191–209, 2002.

- [20] A. Ishigami, T. Ohsawa, M. Hiratsuka et al., "Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease," *Journal of Neuroscience Research*, vol. 80, no. 1, pp. 120–128, 2005.
- [21] N. K. Acharya, E. P. Nagele, M. Han et al., "Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease," *Journal of Autoimmunity*, vol. 38, no. 4, pp. 369–380, 2012.
- [22] G. Berlyne, "Carbamylated proteins and peptides in health and in uremia," *Nephron*, vol. 79, no. 2, pp. 125–130, 1998.
- [23] D. Dobritzsch, I. Lindh, H. Uysal et al., "Crystal structure of an arthritogenic anticollagen immune complex," *Arthritis & Rheumatism*, vol. 63, no. 12, pp. 3740–3748, 2011.
- [24] H. Burkhardt, B. Sehnert, R. Bockermann, Å. Engström, J. R. Kalden, and R. Holmdahl, "Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis," *European Journal of Immunology*, vol. 35, no. 5, pp. 1643–1652, 2005.
- [25] O. Snir, M. Widhe, C. Von Spee et al., "Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles," *Annals of the Rheumatic Diseases*, vol. 68, no. 5, pp. 736–743, 2009.
- [26] P. Mydel, Z. Wang, M. Brisslert et al., "Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis," *Journal of Immunology*, vol. 184, no. 12, pp. 6882–6890, 2010.
- [27] S. Turunen, M.-K. Koivula, L. Risteli, and J. Risteli, "Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits," *Arthritis & Rheumatism*, vol. 62, no. 11, pp. 3345–3352, 2010.
- [28] H. Uysal, R. Bockermann, K. S. Nandakumar et al., "Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis," *The Journal of Experimental Medicine*, vol. 206, no. 2, pp. 449–462, 2009.
- [29] W.-U. Kim, M.-L. Cho, Y. O. Jung et al., "Type II collagen autoimmunity in rheumatoid arthritis," *The American Journal of the Medical Sciences*, vol. 327, no. 4, pp. 202–211, 2004.
- [30] K. S. Nandakumar, M. Andrén, P. Martinsson et al., "Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB," *European Journal of Immunology*, vol. 33, no. 8, pp. 2269–2277, 2003.
- [31] R. Holmdahl, R. Bockermann, J. Bäcklund, and H. Yamada, "The molecular pathogenesis of collagen-induced arthritis in mice—a model for rheumatoid arthritis," *Ageing Research Reviews*, vol. 1, no. 1, pp. 135–147, 2002.
- [32] M. J. Rowley, K. Nandakumar, and R. Holmdahl, "The role of collagen antibodies in mediating arthritis," *Modern Rheumatology*, vol. 18, no. 5, pp. 429–441, 2008.
- [33] Y.-G. Cho, M.-L. Cho, S.-Y. Min, and H.-Y. Kim, "Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis," *Autoimmunity Reviews*, vol. 7, no. 1, pp. 65–70, 2007.
- [34] A. M. Croxford, S. Whittingham, D. McNaughton, K. S. Nandakumar, R. Holmdahl, and M. J. Rowley, "Type II collagen-specific antibodies induce cartilage damage in mice independent of inflammation," *Arthritis & Rheumatism*, vol. 65, no. 3, pp. 650–659, 2013.
- [35] J. Rönnelid, M. C. Wick, J. Lampa et al., "Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression," *Annals of the Rheumatic Diseases*, vol. 64, no. 12, pp. 1744–1749, 2005.
- [36] Y. O. Teng, G. Wheeler, V. E. Hogan et al., "Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity," *Arthritis Research & Therapy*, vol. 14, no. 2, article R57, 2012.
- [37] N. A. Andriopoulos, J. Mestecky, E. J. Miller, and E. L. Bradley, "Antibodies to native and denatured collagens in sera of patients with rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 19, no. 3, pp. 613–617, 1976.
- [38] R. Strollo, F. Ponchel, V. Malmström et al., "Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 65, no. 7, pp. 1702–1712, 2013.
- [39] H. R. Griffiths, "Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease?" *Autoimmunity Reviews*, vol. 7, no. 7, pp. 544–549, 2008.
- [40] M. Sebbag, S. Chapuy-Regaud, I. Auger et al., "Clinical and pathophysiological significance of the autoimmune response to citrullinated proteins in rheumatoid arthritis," *Joint Bone Spine*, vol. 71, no. 6, pp. 493–502, 2004.
- [41] B. J. Young, R. K. Mallya, and R. D. Leslie, "Anti-keratin antibodies in rheumatoid arthritis," *British Medical Journal*, vol. 2, no. 6182, pp. 97–99, 1979.
- [42] P. Kurki, K. Aho, T. Palosuo, and M. Heliovaara, "Immunopathology of rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 35, no. 8, pp. 914–917, 1992.
- [43] J. Sokolove, R. Bromberg, K. D. Deane et al., "Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis," *PLoS ONE*, vol. 7, no. 5, Article ID e35296, 2012.
- [44] S. Rantapää-Dahlqvist, B. A. W. de Jong, E. Berglin et al., "Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 48, no. 10, pp. 2741–2749, 2003.
- [45] V. Gomes-Daudrix, M. Sebbag, E. Girbal et al., "Immunoblotting detection of so-called 'antikeratin antibodies': a new assay for the diagnosis of rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 53, no. 11, pp. 735–742, 1994.
- [46] C. Vincent, M. Simon, M. Sebbag et al., "Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis," *The Journal of Rheumatology*, vol. 25, no. 5, pp. 838–846, 1998.
- [47] C. Vincent, F. de Keyser, C. Masson-Bessière, M. Sebbag, E. M. Veys, and G. Serre, "Anti-perinuclear factor compared with the so called 'antikeratin' antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides," *Annals of the Rheumatic Diseases*, vol. 58, no. 1, pp. 42–48, 1999.
- [48] G. Serre, "Autoantibodies to filaggrin/deiminated fibrin (AFA) are useful for the diagnosis and prognosis of rheumatoid arthritis, and are probably involved in the pathophysiology of the disease," *Joint Bone Spine*, vol. 68, no. 2, pp. 103–105, 2001.
- [49] C. Vincent, L. Nogueira, M. Sebbag et al., "Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 46, no. 8, pp. 2051–2058, 2002.

- [50] L. De Rycke, I. Peene, I. E. A. Hoffman et al., "Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnosis value, associations with radiological progression rate, and extra-articular manifestations," *Annals of the Rheumatic Diseases*, vol. 63, no. 12, pp. 1587–1593, 2004.
- [51] B. V. Cruyssen, T. Cantaert, L. Nogueira et al., "Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays," *Arthritis Research & Therapy*, vol. 8, no. 4, article R122, 2006.
- [52] L. Nogueira, M. Sebbag, C. Vincent et al., "Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 60, no. 9, pp. 882–887, 2001.
- [53] G. A. Schellekens, H. Visser, B. A. de Jong et al., "The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide," *Arthritis & Rheumatism*, vol. 43, no. 1, pp. 155–163, 2000.
- [54] V. Goëb, F. Jouen, D. Gilbert, X. Le Loët, F. Tron, and O. Vittecoq, "Diagnostic and prognostic usefulness of antibodies to citrullinated peptides," *Joint Bone Spine*, vol. 76, no. 4, pp. 343–349, 2009.
- [55] G. M. Alenius, "Psoriatic arthritis-new insights give new options for treatment," *Current Medicinal Chemistry*, vol. 14, no. 3, pp. 359–366, 2007.
- [56] A. Hendler, T. K. Mulli, F. J. Hughes et al., "Involvement of autoimmunity in the pathogenesis of aggressive periodontitis," *Journal of Dental Research*, vol. 89, no. 12, pp. 1389–1394, 2010.
- [57] S. Chapuy-Regaud, L. Nogueira, C. Clavel, M. Sebbag, C. Vincent, and G. Serre, "IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin," *Clinical & Experimental Immunology*, vol. 139, no. 3, pp. 542–550, 2005.
- [58] C. Masson-Bessière, M. Sebbag, E. Girbal-Neuhausser et al., "The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α - and β -chains of fibrin," *The Journal of Immunology*, vol. 166, no. 6, pp. 4177–4184, 2001.
- [59] M. Sebbag, N. Moinard, I. Auger et al., "Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins," *European Journal of Immunology*, vol. 36, no. 8, pp. 2250–2263, 2006.
- [60] E. Girbal-Neuhausser, J.-J. Durieux, M. Arnaud et al., "The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro) filaggrin by deimination of arginine residues," *The Journal of Immunology*, vol. 162, no. 1, pp. 585–594, 1999.
- [61] E. B. Roth, E. Theander, E. Londos et al., "Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease," *Scandinavian Journal of Immunology*, vol. 67, no. 6, pp. 626–631, 2008.
- [62] M. A. Moscarello, F. G. Mastronardi, and D. D. Wood, "The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis," *Neurochemical Research*, vol. 32, no. 2, pp. 251–256, 2007.
- [63] Z. Baka, P. Barta, G. Losonczy et al., "Specific expression of PAD4 and citrullinated proteins in lung cancer is not associated with anti-CCP antibody production," *International Immunology*, vol. 23, no. 6, pp. 405–414, 2011.
- [64] S. C. Stadler, C. T. Vincent, V. D. Fedorova et al., "Dysregulation of PAD4-mediated citrullination of nuclear GSK3 β activates TGF- β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 29, pp. 11851–11856, 2013.
- [65] C. Foulquier, M. Sebbag, C. Clavel et al., "Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation," *Arthritis & Rheumatism*, vol. 56, no. 11, pp. 3541–3553, 2007.
- [66] V. Romero, J. Fert-Bober, P. A. Nigrovic et al., "Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis," *Science Translational Medicine*, vol. 5, no. 209, Article ID 209ra150, 2013.
- [67] H. Bang, K. Egerer, A. Gauliard et al., "Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 56, no. 8, pp. 2503–2511, 2007.
- [68] A. Kinloch, V. Tatzer, R. Wait et al., "Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 7, no. 6, pp. R1421–R1429, 2005.
- [69] A. H. M. van der Helm-van Mil, K. N. Verpoort, F. C. Breedveld, R. E. M. Toes, and T. W. J. Huizinga, "Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 7, no. 5, pp. R949–R958, 2005.
- [70] L. M. Jansen, D. van Schaardenburg, I. E. van der Horst-Bruinsma, R. J. van de Stadt, M. H. M. T. de Koning, and B. A. C. Dijkman, "The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis," *The Journal of Rheumatology*, vol. 30, no. 8, pp. 1691–1695, 2003.
- [71] S. W. Syversen, P. I. Gaarder, G. L. Goll et al., "High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study," *Annals of the Rheumatic Diseases*, vol. 67, no. 2, pp. 212–217, 2008.
- [72] K. P. Machold, T. A. Stamm, V. P. K. Nell et al., "Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease," *Rheumatology*, vol. 46, no. 2, pp. 342–349, 2007.
- [73] S. W. Syversen, P. I. Gaarder, G. L. Goll et al., "High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study," *Annals of the Rheumatic Diseases*, vol. 67, no. 2, pp. 212–217, 2008.
- [74] F. Aubart, B. Crestani, P. Nicaise-Roland et al., "High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis," *The Journal of Rheumatology*, vol. 38, no. 6, pp. 979–982, 2011.
- [75] L. Klareskog, P. Stolt, K. Lundberg et al., "A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination," *Arthritis & Rheumatism*, vol. 54, no. 1, pp. 38–46, 2006.
- [76] C. Vincent, G. Serre, F. Lapeyre et al., "High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies,'"

- Annals of the Rheumatic Diseases*, vol. 48, no. 9, pp. 712–722, 1989.
- [77] E. Berglin, T. Johansson, U. Sundin et al., “Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset,” *Annals of the Rheumatic Diseases*, vol. 65, no. 4, pp. 453–458, 2006.
- [78] F. A. van Gaalen, S. P. Linn-Rasker, W. J. van Venrooij et al., “Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study,” *Arthritis & Rheumatism*, vol. 50, no. 3, pp. 709–715, 2004.
- [79] D. Aletaha, T. Neogi, A. J. Silman et al., “2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” *Annals of the Rheumatic Diseases*, vol. 69, no. 9, pp. 1580–1589, 2010.
- [80] S. Modi, M. Soejima, and M. C. Levesque, “The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses,” *Clinical & Experimental Immunology*, vol. 173, no. 1, pp. 8–17, 2013.
- [81] T. R. Mikuls, J. R. O’Dell, J. A. Stoner et al., “Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody,” *Arthritis & Rheumatism*, vol. 50, no. 12, pp. 3776–3782, 2004.
- [82] Y. Braun-Moscovici, D. Markovits, O. Zinder et al., “Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor- α therapy in patients with rheumatoid arthritis,” *The Journal of Rheumatology*, vol. 33, no. 3, pp. 497–500, 2006.
- [83] H. A. Chen, K. C. Lin, C. H. Chen et al., “The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 65, no. 1, pp. 35–39, 2006.
- [84] C. Alessandri, R. Priori, M. Modesti, R. Mancini, and G. Valesini, “The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis,” *Clinical Reviews in Allergy & Immunology*, vol. 34, no. 1, pp. 45–49, 2008.
- [85] C. Alessandri, M. Bombardieri, N. Papa et al., “Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF α therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement,” *Annals of the Rheumatic Diseases*, vol. 63, no. 10, pp. 1218–1221, 2004.
- [86] F. Bobbio-Pallavicini, R. Caporali, C. Alpini, R. Moratti, and C. Montecucco, “Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF- α treated patients,” *Annals of the New York Academy of Sciences*, vol. 1109, no. 1, pp. 287–295, 2007.
- [87] Y. Allanore, J. Sellam, F. Batteux, C. Job Deslandre, B. Weill, and A. Kahan, “Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab,” *Clinical and Experimental Rheumatology*, vol. 22, no. 6, pp. 756–758, 2004.
- [88] F. Atzeni, P. Sarzi-Puttini, D. Dell’Acqua et al., “Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study,” *Arthritis Research & Therapy*, vol. 8, no. 1, article R3, 2006.
- [89] M. Benucci, S. Turchini, P. Parrochi et al., “Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF- α blockers,” *Recenti Progressi in Medicina*, vol. 97, no. 3, pp. 134–139, 2006.
- [90] W. H. Bos, G. M. Bartelds, M. Vis et al., “Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 68, no. 4, pp. 558–563, 2009.
- [91] M. Cuchacovich, D. Catalan, E. Wainstein et al., “Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 26, no. 6, pp. 1067–1073, 2008.
- [92] M. Vis, W. H. Bos, G. Wolbink et al., “IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis,” *The Journal of Rheumatology*, vol. 35, no. 3, pp. 425–428, 2008.
- [93] P. Taylor, J. Gartemann, J. Hsieh, and J. Creeden, “A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis,” *Autoimmune Diseases*, vol. 2011, Article ID 815038, 18 pages, 2011.
- [94] N. Bizzaro, “Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis,” *Clinical Chemistry and Laboratory Medicine*, vol. 45, no. 2, pp. 150–157, 2007.
- [95] F. Bobbio-Pallavicini, C. Alpini, R. Caporali, S. Avalu, S. Bugatti, and C. Montecucco, “Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment,” *Arthritis Research & Therapy*, vol. 6, no. 3, pp. R264–R272, 2004.
- [96] L. De Rycke, X. Verhelst, E. Kruithof et al., “Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 64, no. 2, pp. 299–302, 2005.
- [97] R. Nissinen, M. Leirisalo-Repo, R. Peltomaa, T. Palosuo, and O. Vaarala, “Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 63, no. 6, pp. 681–687, 2004.
- [98] R. M. Thurlings, K. Vos, C. A. Wijbrandts, A. H. Zwinderman, D. M. Gerlag, and P. P. Tak, “Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response,” *Annals of the Rheumatic Diseases*, vol. 67, no. 7, pp. 917–925, 2008.
- [99] G. Cambridge, M. J. Leandro, J. C. W. Edwards et al., “Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis,” *Arthritis & Rheumatism*, vol. 48, no. 8, pp. 2146–2154, 2003.
- [100] T. G. Kormelink, J. Tekstra, R. M. Thurlings et al., “Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity,” *Annals of the Rheumatic Diseases*, vol. 69, no. 12, pp. 2137–2144, 2010.
- [101] S. Rosengren, N. Wei, K. C. Kalunian, N. J. Zvaifler, A. Kavanaugh, and D. L. Boyle, “Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab,” *Arthritis Research & Therapy*, vol. 10, no. 5, article R105, 2008.
- [102] E. Toubi, A. Kessel, G. Slobodin et al., “Changes in macrophage function after rituximab treatment in patients with rheumatoid

- arthritis," *Annals of the Rheumatic Diseases*, vol. 66, no. 6, pp. 818–820, 2007.
- [103] Y. Teng, R. J. Verburg, K. N. Verpoort et al., "Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study," *Arthritis Research & Therapy*, vol. 9, no. 5, article R106, 2007.
- [104] S. Jaisson, C. Pietrement, and P. Gillery, "Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis," *Clinical Chemistry*, vol. 57, no. 11, pp. 1499–1505, 2011.
- [105] S. Jaisson and P. Gillery, "Evaluation of nonenzymatic post-translational modification-derived products as biomarkers of molecular aging of proteins," *Clinical Chemistry*, vol. 56, no. 9, pp. 1401–1412, 2010.
- [106] Z. Wang, S. J. Nicholls, E. R. Rodriguez et al., "Protein carbamylation links inflammation, smoking, uremia and atherogenesis," *Nature Medicine*, vol. 13, no. 10, pp. 1176–1184, 2007.
- [107] D. Golemi, L. Maveyraud, S. Vakulenko, J.-P. Samama, and S. Mobashery, "Critical involvement of a carbamylated lysine in catalytic function of class D β -lactamases," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 25, pp. 14280–14285, 2001.
- [108] L. M. Kraus, L. Gaber, C. R. Handorf, H.-P. Marti, and A. P. Kraus Jr., "Carbamoylation of glomerular and tubular proteins in patients with kidney failure: a potential mechanism of ongoing renal damage," *Swiss Medical Weekly*, vol. 131, no. 11–12, pp. 139–145, 2001.
- [109] S. Higashi and K. Miyazaki, "Reactive site-modified tissue inhibitor of metalloproteinases-2 inhibits the cell-mediated activation of progelatinase A," *Journal of Biological Chemistry*, vol. 274, no. 15, pp. 10497–10504, 1999.
- [110] M. Oimomi, H. Hatanaka, and Y. Yoshimura, "Carbamylation of insulin and its biological activity," *Nephron*, vol. 46, no. 1, pp. 63–66, 1987.
- [111] F. Grande, S. Grisolia, and D. Diederich, "On the biological and chemical reactivity of carbamylated glucagon," *Proceedings of the Society for Experimental Biology and Medicine*, vol. 139, no. 3, pp. 855–860, 1972.
- [112] K. Ishikawa, H. Hatanaka, and T. Kawasaki, "Studies on the modification of hormones in patients with renal failure and clinical evaluation—with reference to carbamylated ACTH and insulin," *Nihon Jinzo Gakkai Shi*, vol. 27, no. 11, pp. 1605–1609, 1985.
- [113] T. R. Coleman, C. Westenfelder, F. E. Tögel et al., "Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and activities," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 15, pp. 5965–5970, 2006.
- [114] J. Lippincott and I. Apostol, "Carbamylation of cysteine: a potential artifact in peptide mapping of hemoglobins in the presence of urea," *Analytical Biochemistry*, vol. 267, no. 1, pp. 57–64, 1999.
- [115] S. Jaisson, C. Delevallée-Forte, F. Touré, P. Rieu, R. Garnotel, and P. Gillery, "Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst," *FEBS Letters*, vol. 581, no. 7, pp. 1509–1513, 2007.
- [116] S. Jaisson, V. Larreta-Garde, G. Bellon, W. Hornebeck, R. Garnotel, and P. Gillery, "Carbamylation differentially alters type I collagen sensitivity to various collagenases," *Matrix Biology*, vol. 26, no. 3, pp. 190–196, 2007.
- [117] S. Jaisson, S. Lorimier, S. Ricard-Blum et al., "Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils," *Chemistry & Biology*, vol. 13, no. 2, pp. 149–159, 2006.
- [118] M. Scinocca, D. A. Bell, M. Racapé et al., "Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides," *The Journal of Rheumatology*, vol. 41, no. 2, Article ID 130742, pp. 270–279, 2014.
- [119] S. Sirpal, "Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease," *Clinical Science*, vol. 116, no. 9, pp. 681–695, 2009.
- [120] A. G. Basnakian, S. V. Shah, E. Ok, E. Altunel, and E. O. Apostolov, "Carbamylated LDL," *Advances in Clinical Chemistry*, vol. 51, pp. 25–52, 2010.
- [121] E. O. Apostolov, A. G. Basnakian, E. Ok, and S. V. Shah, "Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease," *Journal of Renal Nutrition*, vol. 22, no. 1, pp. 134–138, 2012.
- [122] E. O. Apostolov, S. V. Shah, E. Ok, and A. G. Basnakian, "Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 27, no. 4, pp. 826–832, 2007.
- [123] E. O. Apostolov, D. Ray, A. V. Savenka, S. V. Shah, and A. G. Basnakian, "Chronic uremia stimulates LDL carbamylation and atherosclerosis," *Journal of the American Society of Nephrology*, vol. 21, no. 11, pp. 1852–1857, 2010.
- [124] S. Swaminathan and S. V. Shah, "Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease," *Kidney International*, vol. 80, no. 5, pp. 453–463, 2011.
- [125] R. Garnotel, N. Sabbah, S. Jaisson, and P. Gillery, "Enhanced activation of and increased production of matrix metalloproteinase-9 by human blood monocytes upon adhering to carbamylated collagen," *FEBS Letters*, vol. 563, no. 1–3, pp. 13–16, 2004.
- [126] H. Bang, K. Karl, F. Anette, B. Eugen, and R. Gerd, "Carbamoylation of vimentin in patients with rheumatoid arthritis: identification of a novel protein modification with a possible link to disease pathogenesis," *Arthritis & Rheumatism*, vol. 63, supplement 10, article 1745, 2011.
- [127] J. A. Hill, S. Southwood, A. Sette, A. M. Jevnikar, D. A. Bell, and E. Cairns, "Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule," *The Journal of Immunology*, vol. 171, no. 2, pp. 538–541, 2003.
- [128] J. A. Hill, D. A. Bell, W. Brintnell et al., "Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice," *The Journal of Experimental Medicine*, vol. 205, no. 4, pp. 967–979, 2008.
- [129] J. Shi, L. A. van de Stadt, E. W. Levarht et al., "Brief Report: anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 65, no. 4, pp. 911–915, 2013.
- [130] A. Willemze, R. E. Toes, T. W. Huizinga, and L. A. Trouw, "New biomarkers in rheumatoid arthritis," *The Netherlands Journal of Medicine*, vol. 70, no. 9, pp. 392–399, 2012.
- [131] H. van Dongen, J. van Aken, L. R. Lard et al., "Efficacy of methotrexate treatment in patients with probable rheumatoid

- arthritis: a double-blind, randomized, placebo-controlled trial," *Arthritis & Rheumatism*, vol. 56, no. 5, pp. 1424–1432, 2007.
- [132] A. H. M. van der Helm-van Mil, S. L. Cessie, H. van Dongen, F. C. Breedveld, R. E. M. Toes, and T. W. J. Huizinga, "A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions," *Arthritis & Rheumatism*, vol. 56, no. 2, pp. 433–440, 2007.
- [133] A. L. Young, W. G. Carter, H. A. Doyle, M. J. Mamula, and D. W. Aswad, "Structural integrity of histone H₂B *in vivo* requires the activity of protein L-isoaspartate O-methyltransferase, a putative protein repair enzyme," *Journal of Biological Chemistry*, vol. 276, no. 40, pp. 37161–37165, 2001.
- [134] H. R. Griffiths, L. Möller, G. Bartosz et al., "Biomarkers," *Molecular Aspects of Medicine*, vol. 23, no. 1–3, pp. 101–208, 2002.
- [135] H. R. Griffiths and J. Lunec, "Effects of reactive oxygen species on immunoglobulin G function," *Molecular Aspects of Medicine*, vol. 12, no. 2, pp. 107–119, 1991.
- [136] L. Dai, D. J. Lamb, D. S. Leake et al., "Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients," *Free Radical Research*, vol. 32, no. 6, pp. 479–486, 2000.
- [137] G. D. Kitas and N. Erb, "Tackling ischaemic heart disease in rheumatoid arthritis," *Rheumatology*, vol. 42, no. 5, pp. 607–613, 2003.
- [138] H. Kaur and B. Halliwell, "Evidence for nitric oxide-mediated oxidative damage in chronic inflammation nitrotyrosine in serum and synovial fluid from rheumatoid patients," *FEBS Letters*, vol. 350, no. 1, pp. 9–12, 1994.
- [139] P. G. Winyard, B. Ryan, P. Eggleton et al., "Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease," *Biochemical Society Transactions*, vol. 39, no. 5, pp. 1226–1232, 2011.
- [140] L. E. Adams, S. M. Roberts, R. Donovan-Brand, H. Zimmer, and E. V. Hess, "Study of procainamide hapten-specific antibodies in rabbits and humans," *International Journal of Immunopharmacology*, vol. 15, no. 8, pp. 887–897, 1993.
- [141] K. Raza, M. Breese, P. Nightingale et al., "Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis," *The Journal of Rheumatology*, vol. 32, no. 2, pp. 231–238, 2005.
- [142] D. W. Aswad, M. V. Paranandi, and B. T. Schurter, "Isoaspartate in peptides and proteins: formation, significance, and analysis," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 21, no. 6, pp. 1129–1136, 2000.
- [143] D. Ingrosso, S. D'Angelo, E. di Carlo, A. F. Perna, V. Zappia, and P. Galletti, "Increased methyl esterification of altered aspartyl residues erythrocyte membrane proteins in response to oxidative stress," *European Journal of Biochemistry*, vol. 267, no. 14, pp. 4397–4405, 2000.
- [144] M. J. Mamula, R. J. Gee, J. I. Elliott et al., "Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins," *Journal of Biological Chemistry*, vol. 274, no. 32, pp. 22321–22327, 1999.
- [145] M.-L. Yang, H. A. Doyle, R. J. Gee et al., "Intracellular protein modification associated with altered T cell functions in autoimmunity," *The Journal of Immunology*, vol. 177, no. 7, pp. 4541–4549, 2006.
- [146] D. J. Pattison and P. G. Winyard, "Dietary antioxidants in inflammatory arthritis: do they have any role in etiology or therapy?" *Nature Clinical Practice Rheumatology*, vol. 4, no. 11, pp. 590–596, 2008.
- [147] P. A. Kirkham, G. Caramori, P. Casolari et al., "Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease," *American Journal of Respiratory and Critical Care Medicine*, vol. 184, no. 7, pp. 796–802, 2011.
- [148] H. A. Al-Shobaili, A. A. A. Robaee, A. Alzolibani, M. I. Khan, and Z. Rasheed, "Hydroxyl radical modification of Immunoglobulin G generated cross-reactive antibodies: its potential role in systemic lupus erythematosus," *Clinical Medicine Insights*, vol. 4, pp. 11–19, 2011.
- [149] V. Chiurchiù and M. Maccarrone, "Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities," *Antioxidants and Redox Signaling*, vol. 15, no. 9, pp. 2605–2641, 2011.
- [150] N. V. Blough and O. C. Zafriou, "Reaction of superoxide with nitric oxide to form peroxonitrite in alkaline aqueous solution," *Inorganic Chemistry*, vol. 24, no. 22, pp. 3502–3504, 1985.
- [151] J. K. Sandhu, S. Robertson, H. C. Birnboim, and R. Goldstein, "Distribution of protein nitrotyrosine in synovial tissues of patients with rheumatoid arthritis and osteoarthritis," *The Journal of Rheumatology*, vol. 30, no. 6, pp. 1173–1181, 2003.
- [152] F. Khan and A. A. Siddiqui, "Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus," *Clinica Chimica Acta*, vol. 370, no. 1–2, pp. 100–107, 2006.
- [153] R. Singh, A. Barden, T. Mori, and L. Beilin, "Advanced glycation end-products: a review," *Diabetologia*, vol. 44, no. 2, pp. 129–146, 2001.
- [154] S. Ligier, P. Fortin, and M. Newkirk, "A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE," *Rheumatology*, vol. 37, no. 12, pp. 1307–1314, 1998.
- [155] S. Viguet-Carrin, J. P. Roux, M. E. Arlot et al., "Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae," *Bone*, vol. 39, no. 5, pp. 1073–1079, 2006.
- [156] S. Drinda, S. Franke, C. C. Canet et al., "Identification of the advanced glycation end products N ϵ -carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 61, no. 6, pp. 488–492, 2002.
- [157] S. Drinda, S. Franke, M. Rüster et al., "Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis," *Rheumatology International*, vol. 25, no. 6, pp. 411–413, 2005.
- [158] J. R. Chen, M. Takahashi, M. Suzuki, K. Kushida, S. Miyamoto, and T. Inoue, "Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis," *Rheumatology*, vol. 38, no. 12, pp. 1275–1278, 1999.
- [159] L. K. Stamp, I. Khalilova, J. M. Tarr et al., "Myeloperoxidase and oxidative stress in rheumatoid arthritis," *Rheumatology*, vol. 51, no. 10, pp. 1796–1803, 2012.
- [160] C. Bergt, X. Fu, N. P. Huq, J. Kao, and J. W. Heinecke, "Lysine residues direct the chlorination of tyrosines in YXXK motifs of apolipoprotein A-I when hypochlorous acid oxidizes high density lipoprotein," *Journal of Biological Chemistry*, vol. 279, no. 9, pp. 7856–7866, 2004.
- [161] L. Dai, Z. Zhang, P. G. Winyard et al., "A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid," *Free Radical Biology and Medicine*, vol. 22, no. 4, pp. 705–710, 1996.

- [162] C. A. Hitchon and H. S. El-Gabalawy, "Oxidation in rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 6, no. 6, pp. 265–278, 2004.
- [163] M. M. Newkirk, K. LePage, T. Niwa, and L. Rubin, "Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA)," *Cellular and Molecular Biology*, vol. 44, no. 7, pp. 1129–1138, 1998.
- [164] M. M. Newkirk, R. Goldbach-Mansky, J. Lee et al., "Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis," *Arthritis Research & Therapy*, vol. 5, no. 2, pp. R82–R90, 2003.
- [165] S. Grinnell, K. Yoshida, and H. E. Jasin, "Responses of lymphocytes of patients with rheumatoid arthritis to IgG modified by oxygen radicals or peroxynitrite," *Arthritis & Rheumatism*, vol. 52, no. 1, pp. 80–83, 2005.
- [166] B. T. Kurien and R. H. Scofield, "Autoimmunity and oxidatively modified autoantigens," *Autoimmunity Reviews*, vol. 7, no. 7, pp. 567–573, 2008.
- [167] S. Jaswal, H. C. Mehta, A. K. Sood, and J. Kaur, "Antioxidant status in rheumatoid arthritis and role of antioxidant therapy," *Clinica Chimica Acta*, vol. 338, no. 1-2, pp. 123–129, 2003.
- [168] A. J. Bailey, T. J. Sims, N. C. Avery, and E. P. Halligan, "Non-enzymic glycation of fibrous collagen: reaction produces of glucose and ribose," *Biochemical Journal*, vol. 305, no. 2, pp. 385–390, 1995.
- [169] K. P. Liao, M. Gunnarsson, H. Källberg et al., "Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 60, no. 3, pp. 653–660, 2009.
- [170] H. Lemarechal, Y. Allanore, C. Chenevier-Gobeaux, A. Kahan, O. G. Ekindjian, and D. Borderie, "Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy," *Clinica Chimica Acta*, vol. 372, no. 1-2, pp. 147–153, 2006.
- [171] Y. Kageyama, M. Takahashi, T. Ichikawa, E. Torikai, and A. Nagano, "Reduction of oxidative stress marker levels by anti-TNF- α antibody, infliximab, in patients with rheumatoid arthritis," *Clinical and Experimental Rheumatology*, vol. 26, no. 1, pp. 73–80, 2008.
- [172] Y. Kageyama, M. Takahashi, T. Nagafusa, E. Torikai, and A. Nagano, "Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis," *Rheumatology International*, vol. 28, no. 3, pp. 245–251, 2008.
- [173] I. Túnez, M. Feijóo, G. Huerta et al., "The effect of infliximab on oxidative stress in chronic inflammatory joint disease," *Current Medical Research and Opinion*, vol. 23, no. 6, pp. 1259–1267, 2007.
- [174] M. Grootveld, E. B. Henderson, A. Farrell, D. R. Blake, H. G. Parkes, and P. Haycock, "Oxidative damage to hyaluronate and glucose in synovial fluid during exercise of the inflamed rheumatoid joint. Detection of abnormal low-molecular-mass metabolites by proton-nmr spectroscopy," *Biochemical Journal*, vol. 273, no. 2, pp. 459–467, 1991.
- [175] D. Rowley, J. M. C. Gutteridge, and D. Blake, "Lipid peroxidation in rheumatoid arthritis-thiobarbituric acid-reactive material and catalytic iron salts in synovial fluid from rheumatoid patients," *Clinical Science*, vol. 66, no. 6, pp. 691–695, 1984.
- [176] S. Taysi, F. Polat, M. Gul, R. Sari, and E. Bakan, "Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis," *Rheumatology International*, vol. 21, no. 5, pp. 200–204, 2002.
- [177] E. S. Lourida, A. N. Georgiadis, E. C. Papavasiliou, A. I. Papathanasiou, A. A. Drosos, and A. D. Tselepis, "Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2," *Arthritis Research & Therapy*, vol. 9, no. 1, article R19, 2007.
- [178] I. Dalle-Donne, R. Rossi, D. Giustarini, A. Milzani, and R. Colombo, "Protein carbonyl groups as biomarkers of oxidative stress," *Clinica Chimica Acta*, vol. 329, no. 1-2, pp. 23–38, 2003.
- [179] Y. Henrotin, P. Bruckner, and J.-P. Pujol, "The role of reactive oxygen species in homeostasis and degradation of cartilage," *Osteoarthritis and Cartilage*, vol. 11, no. 10, pp. 747–755, 2003.
- [180] C. C. Winterbourn and A. J. Kettle, "Biomarkers of myeloperoxidase-derived hypochlorous acid," *Free Radical Biology and Medicine*, vol. 29, no. 5, pp. 403–409, 2000.
- [181] R. Laczik, P. Szodoray, K. Veres et al., "Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome," *Lupus*, vol. 20, no. 7, pp. 730–735, 2011.
- [182] V. F. Thromb, "Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology," *Circulation*, vol. 90, no. 4 I, pp. 2126–2146, 1994.
- [183] J. Cvetkovic, S. Wällberg-Jonsson, E. Ahmed, S. Rantapää-Dahlqvist, and A. K. Lefvert, "Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis," *Rheumatology*, vol. 41, no. 9, pp. 988–995, 2002.
- [184] R. Wu, E. Svenungsson, I. Gunnarsson et al., "Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE," *Lupus*, vol. 8, no. 2, pp. 142–150, 1999.
- [185] G. Hayem, P. Nicaise-Roland, E. Palazzo et al., "Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome," *Lupus*, vol. 10, no. 5, pp. 346–351, 2001.
- [186] D. Zhao, H. Ogawa, X. Wang et al., "Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis," *American Journal of Clinical Pathology*, vol. 116, no. 5, pp. 760–767, 2001.
- [187] O. Amengual, T. Atsumi, M. A. Khamashta, F. Tinahones, and G. R. V. Hughes, "Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome," *Rheumatology*, vol. 36, no. 9, pp. 964–968, 1997.
- [188] T. J. Orchard, G. Virella, K. Y.-Z. Forrest, R. W. Evans, D. J. Becker, and M. F. Lopes-Virella, "Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh epidemiology of diabetes complications study," *Diabetes*, vol. 48, no. 7, pp. 1454–1458, 1999.
- [189] G. Bellomo, E. Maggi, M. Poli, F. G. Agosta, P. Bollati, and G. Finardi, "Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM," *Diabetes*, vol. 44, no. 1, pp. 60–66, 1995.
- [190] D. O'Byrne, S. Devaraj, K. N. Islam et al., "Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy," *Metabolism*, vol. 50, no. 2, pp. 207–215, 2001.
- [191] H. Itabe, E. Takeshima, H. Iwasaki et al., "A monoclonal antibody against oxidized lipoprotein recognizes foam cells

- in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides," *Journal of Biological Chemistry*, vol. 269, no. 21, pp. 15274–15279, 1994.
- [192] H. C. Boyd, A. M. Gown, G. Wolfbauer, and A. Chait, "Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit," *The American Journal of Pathology*, vol. 135, no. 5, pp. 815–825, 1989.
- [193] Y. Shoenfeld, R. Wu, L. D. Dearing, and E. Matsuura, "Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?" *Circulation*, vol. 110, no. 17, pp. 2552–2558, 2004.
- [194] S. Stemme, B. Faber, J. Holm, O. Wiklund, J. L. Witztum, and G. K. Hansson, "T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 9, pp. 3893–3897, 1995.
- [195] S. Björkerud and B. Björkerud, "Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability," *The American Journal of Pathology*, vol. 149, no. 2, pp. 367–380, 1996.
- [196] U. P. Steinbrecher, S. Parthasarathy, and D. S. Leake, "Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 81, no. 12, pp. 3883–3887, 1984.
- [197] S. Hörkkö, T. Olee, L. Mo et al., "Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both β_2 -glycoprotein 1 and oxidized low-density lipoprotein," *Circulation*, vol. 103, no. 7, pp. 941–946, 2001.
- [198] S. Hörkkö, E. Miller, E. Dudl et al., "Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein," *Journal of Clinical Investigation*, vol. 98, no. 3, pp. 815–825, 1996.
- [199] A. Tuominen, Y. I. Miller, L. F. Hansen, Y. A. Kesäniemi, J. L. Witztum, and S. Hörkkö, "A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 9, pp. 2096–2102, 2006.
- [200] O. Vaarala, G. Alfthan, M. Jauhainen, M. Leirisalo-Repo, K. Aho, and T. Palosuo, "Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus," *The Lancet*, vol. 341, no. 8850, pp. 923–925, 1993.
- [201] S. Ahmad, S. Habib, Moinuddin, and A. Ali, "Preferential recognition of epitopes on AGE-IgG by the autoantibodies in rheumatoid arthritis patients," *Human Immunology*, vol. 74, no. 1, pp. 23–27, 2013.
- [202] K. Lundberg, S. Nijenhuis, E. R. Vossenaar et al., "Citruinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity," *Arthritis Research & Therapy*, vol. 7, no. 3, pp. R458–R467, 2005.
- [203] K. A. Kuhn, L. Kulik, B. Tomooka et al., "Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis," *Journal of Clinical Investigation*, vol. 116, no. 4, pp. 961–973, 2006.
- [204] C. Clavel, L. Nogueira, L. Laurent et al., "The rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrin (ogen) induce macrophage secretion of TNF- α through engagement of Fc gamma RIIA," *Annals of the Rheumatic Diseases*, vol. 67, supplement 1, p. A2, 2008.
- [205] L. Laurent, C. Clavel, O. Lemaire et al., "Fc γ receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins," *Annals of the Rheumatic Diseases*, vol. 70, no. 6, pp. 1052–1059, 2011.
- [206] E. Westman, K. Lundberg, and H. E. Harris, "Arthritogenicity of collagen type II is increased by chlorination," *Clinical & Experimental Immunology*, vol. 145, no. 2, pp. 339–345, 2006.
- [207] M. Uesugi, K. Yoshida, and H. E. Jasin, "Inflammatory properties of IgG modified by oxygen radicals and peroxynitrite," *The Journal of Immunology*, vol. 165, no. 11, pp. 6532–6537, 2000.
- [208] U. Shahab, S. Ahmad, M. Moinuddin et al., "Hydroxyl radical modification of collagen type II increases its arthritogenicity and immunogenicity," *PLoS ONE*, vol. 7, no. 2, Article ID e31199, 2012.
- [209] O. Kumm, S. P. Turunen, C. Wang et al., "Carbamyl adducts on low-density lipoprotein induce IgG response in *LDLR*^{-/-} mice and bind plasma autoantibodies in humans under enhanced carbamylation," *Antioxidants & Redox Signaling*, vol. 19, no. 10, pp. 1047–1062, 2013.
- [210] W. P. Arend and G. S. Firestein, "Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis," *Nature Reviews Rheumatology*, vol. 8, no. 10, pp. 573–586, 2012.
- [211] M. J. Scinocca, "Immune responses to homocitrullinated protein/peptide in rheumatoid arthritis," The University of Western Ontario-Electronic Thesis and Dissertation Repository, 2012, <http://ir.lib.uwo.ca/etd/774/>.
- [212] M. M. Nielsen, D. van Schaardenburg, H. W. Reesink et al., "Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors," *Arthritis & Rheumatism*, vol. 50, no. 2, pp. 380–386, 2004.
- [213] I. Auger, M. Sebbag, C. Vincent et al., "Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen," *Arthritis & Rheumatism*, vol. 52, no. 11, pp. 3424–3432, 2005.
- [214] J. Ireland, J. Herzog, and E. R. Unanue, "Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization," *The Journal of Immunology*, vol. 177, no. 3, pp. 1421–1425, 2006.
- [215] D. van der Woude, S. Rantapää-Dahlqvist, A. Ioan-Facsinay et al., "Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis," *Annals of the Rheumatic Diseases*, vol. 69, no. 8, pp. 1554–1561, 2010.
- [216] M. Brink, M. Hansson, L. Mathsson et al., "Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 65, no. 4, pp. 899–910, 2013.
- [217] H. Kokkonen, M. Mullazehi, E. Berglin et al., "Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 13, no. 1, article R13, 2011.
- [218] D. van der Woude, S. Rantapää-Dahlqvist, A. Ioan-Facsinay et al., "Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis," *Annals of the Rheumatic Diseases*, vol. 69, no. 8, pp. 1554–1561, 2010.

- [219] K. N. Verpoort, K. Cheung, A. Ioan-Facsinay et al., "Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles," *Arthritis & Rheumatism*, vol. 56, no. 12, pp. 3949–3952, 2007.
- [220] P. Suwannalai, H. U. Scherer, D. van der Woude et al., "Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens," *Annals of the Rheumatic Diseases*, vol. 70, no. 2, pp. 373–379, 2011.
- [221] P. Suwannalai, L. A. van de Stadt, H. Radner et al., "Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 64, no. 5, pp. 1323–1328, 2012.
- [222] P. Suwannalai, K. Britsemmer, R. Knevel et al., "Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 73, no. 1, pp. 270–276, 2014.
- [223] K. N. Verpoort, C. M. Jol-van der Zijde, E. A. M. Papendrecht-van der Voort et al., "Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response," *Arthritis & Rheumatism*, vol. 54, no. 12, pp. 3799–3808, 2006.
- [224] H. U. Scherer, D. van der Woude, A. Ioan-Facsinay et al., "Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid," *Arthritis & Rheumatism*, vol. 62, no. 6, pp. 1620–1629, 2010.
- [225] E. Roth, P. Stenberg, C. Book, and K. Sjöberg, "Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis-new pathways to epitope spreading," *Clinical and Experimental Rheumatology*, vol. 24, no. 1, pp. 12–18, 2006.
- [226] C. L. Vanderlugt and S. D. Miller, "Epitope spreading in immune-mediated diseases: implications for immunotherapy," *Nature Reviews Immunology*, vol. 2, no. 2, pp. 85–95, 2002.
- [227] L. A. van de Stadt, A. R. van der Horst, M. H. M. T. de Koning et al., "The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia," *Annals of the Rheumatic Diseases*, vol. 70, no. 1, pp. 128–133, 2011.
- [228] L. A. van de Stadt, M. H. M. T. de Koning, R. J. van de Stadt et al., "Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 63, no. 11, pp. 3226–3233, 2011.
- [229] F. Murray, L. Israelsson, J. Steen et al., "A5.14 Homocitrulline-reactive antibodies can be generated from synovial B-cells from ACPA-negative RA patients," *Annals of the Rheumatic Diseases*, vol. 72, supplement 1, article A35, 2013.
- [230] A. Schuerwegh, A. Ioan-Facsinay, A. L. Dorjée et al., "Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 6, pp. 2586–2591, 2010.
- [231] G. Lakos, L. Soós, A. Fekete et al., "Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope," *Clinical and Experimental Rheumatology*, vol. 26, no. 2, pp. 253–260, 2008.
- [232] A. Svärd, A. Kastbom, M. K. Söderlin, Å. Reckner-Olsson, and T. Skogh, "A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis," *The Journal of Rheumatology*, vol. 38, no. 7, pp. 1265–1272, 2011.
- [233] A. Svärd, A. Kastbom, Å. Reckner-Olsson, and T. Skogh, "Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project," *Arthritis Research & Therapy*, vol. 10, no. 4, article R75, 2008.
- [234] D. van der Woude, S. W. Syversen, E. I. H. van der Voort et al., "The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 69, no. 6, pp. 1110–1116, 2010.
- [235] P. Suwannalai, L. A. Trouw, R. E. M. Toes, and T. W. J. Huizinga, "Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis," *Modern Rheumatology*, vol. 22, no. 1, pp. 15–20, 2012.
- [236] J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd, and R. A. Dwek, "The impact of glycosylation on the biological function and structure of human immunoglobulins," *Annual Review of Immunology*, vol. 25, pp. 21–50, 2007.
- [237] A. C. Kempers, H. U. Scherer, Y. Rombouts et al., "A1.1 Anti-citrullinated protein antibody specific Fc glycosylation patterns in arthralgia patients," *Annals of the Rheumatic Diseases*, vol. 72, supplement 1, article A1, 2013.
- [238] F. E. van de Geijn, M. Wührer, M. H. J. Selman et al., "Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study," *Arthritis Research & Therapy*, vol. 11, no. 6, article R193, 2009.
- [239] A. Ercan, J. Cui, M. M. Hazen et al., "Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 14, no. 2, article R43, 2012.
- [240] K. Vos, R. M. Thurlings, C. A. Wijbrandts, D. van Schaardenburg, D. M. Gerlag, and P. P. Tak, "Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 56, no. 3, pp. 772–778, 2007.
- [241] C. C. Reparón-Schuijt, W. J. van Esch, C. van Kooten et al., "Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 44, no. 1, pp. 41–47, 2001.
- [242] C. C. Reparón-Schuijt, W. J. van Esch, C. van Kooten, E. W. Levarht, F. C. Breedveld, and C. L. Verweij, "Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients," *Arthritis & Rheumatism*, vol. 41, no. 12, pp. 2211–2220, 1998.
- [243] F. W. Miller, L. Alfredsson, K. H. Costenbader et al., "Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop," *Journal of Autoimmunity*, vol. 39, no. 4, pp. 259–271, 2012.
- [244] P. Stolt, A. Yahya, C. Bengtsson et al., "Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 69, no. 6, pp. 1072–1076, 2010.
- [245] P. Stolt, H. Källberg, I. Lundberg, B. Sjögren, L. Klareskog, and L. Alfredsson, "Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study," *Annals of the Rheumatic Diseases*, vol. 64, no. 4, pp. 582–586, 2005.
- [246] S. Turner and N. Cherry, "Rheumatoid arthritis in workers exposed to silica in the pottery industry," *Occupational and Environmental Medicine*, vol. 57, no. 7, pp. 443–477, 2000.

- [247] C. A. Speck-Hernandez and G. Montoya-Ortiz, "Silicon, a possible link between environmental exposure and autoimmune diseases: the case of rheumatoid arthritis," *Arthritis*, vol. 2012, Article ID 604187, 11 pages, 2012.
- [248] L. Klareskog, L. Padyukov, J. Lorentzen, and L. Alfredsson, "Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis," *Nature Clinical Practice Rheumatology*, vol. 2, no. 8, pp. 425–433, 2006.
- [249] H.-S. Lee, P. Irigoyen, M. Kern et al., "Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts," *Arthritis & Rheumatism*, vol. 56, no. 6, pp. 1745–1753, 2007.
- [250] L. Klareskog, L. Padyukov, J. Rönnelid, and L. Alfredsson, "Genes, environment and immunity in the development of rheumatoid arthritis," *Current Opinion in Immunology*, vol. 18, no. 6, pp. 650–655, 2006.
- [251] C. C. Reparón-Schuijt, W. J. van Esch, C. van Kooten et al., "Presence of a population of CD20+, CD38– B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 44, no. 9, pp. 2029–2037, 2001.
- [252] J. C. Edwards and G. Cambridge, "B-cell targeting in rheumatoid arthritis and other autoimmune diseases," *Nature Reviews Immunology*, vol. 6, no. 5, pp. 394–403, 2006.
- [253] S. Takemura, P. A. Klimiuk, A. Braun, J. J. Goronzy, and C. M. Weyand, "T cell activation in rheumatoid synovium is B cell dependent," *The Journal of Immunology*, vol. 167, no. 8, pp. 4710–4718, 2001.
- [254] A.-K. Tidén, T. Sjögren, M. Svensson et al., "2-Thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation," *Journal of Biological Chemistry*, vol. 286, no. 43, pp. 37578–37589, 2011.
- [255] M. Segelmark, B. Persson, T. Hellmark, and J. Wieslander, "Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin?" *Clinical & Experimental Immunology*, vol. 108, no. 1, pp. 167–174, 1997.

